Principles of antibacterial dosing in continuous renal replacement therapy

Critical Care Medicine

Volumn 37, Issue 7, 2009, Pages 2268-2282

  Choi, Gordon ^a   Gomersall, Charles D ^a   Tian, Qi ^a   Joynt, Gavin M ^a   Freebairn, Ross ^a   Lipman, Jeffrey ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acute; Antibacterial Agents; Critical illness; Kidney failure; Pharmacodynamics; Pharmacokinetics; Renal replacement therapy

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLOXACILLIN; FLUCLOXACILLIN; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; NAFCILLIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICAL ILLNESS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG TISSUE LEVEL; DRUG TRANSPORT; HUMAN; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; DOSE RESPONSE; DRUG ADMINISTRATION; HEMOFILTRATION; METABOLISM; RENAL REPLACEMENT THERAPY;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; RENAL DIALYSIS;

EID: 67649755694     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181aab3d0     Document Type: Review

References (119)

1. Rahman TM, Treacher D: Management of acute renal failure on the intensive care unit. Clin Med 2002; 2:108-113
2. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-123
3. Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 2004; 351: 159-169
4. Roberts JA, Kruger P, Paterson DL, et al: Antibiotic resistance - What's dosing got to do with it? Crit Care Med 2008; 36: 2433-2440
5. Dennesen PJ, van der Ven AJ, Ramsay G, et al: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163:1371-1375
6. Schetz M, Ferdinande P, Van den Berghe G, et al: Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995; 21:612-620
7. Kubin C, Dzierba A: The effects of continuous renal replacement on anti-infective therapy in the critically ill. J Pharm Pract 2005; 18:109-117
8. Roberts JA, Lipman J: Antibacterial dosing in intensive care: Pharmacokinetics, degree of disease, and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45:755-773
9. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10
10. Burgess DS: Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115:19S-23S
11. Tessier PR, Nicolau DP, Onyeji CO, et al: Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy 1999; 45:284-295
12. Roberts JA, Paratz J, Paratz E, et al: Continuous infusion of beta-lactam antibiotics in severe infections: A review of its role. Int J Antimicrob Agents 2007; 30:11-18
13. Mouton JW, Vinks AA: Continuous infusion of beta-lactam. Curr Opin Crit Care 2007; 13:598-606
14. Lipman J, Gomersall CD, Gin T, et al: Continuous infusion ceftazidime in intensive care: A randomised controlled trial. J Antimicrob Chemother 1999; 43:309-311
15. Roberts JA, Boots R, Rickard CM, et al: Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007; 59:285-291
16. Rybak MJ, Abate BJ, Kang SL, et al: Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549-1555
17. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: Importance of the ratio of the peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99
18. Ronco C, Bellomo R, Ricci Z: Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant 2001; 16: 67-72
19. Oda S, Hirasawa H, Shiga H, et al: Continuous hemofiltration/ hemodiafiltration in critical care. Ther Apher 2002; 6:193-198
20. Uchino S: The epidemiology of acute renal failure in the world. Curr Opin Crit Care 2006; 12:538-543
21. Golper TA, Noonan HM, Elzinga L, et al: Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988; 43:565-570
22. Krueger WA, Schroeder TH, Hansen M: Pharmacokinetics of antibiotics during continuous renal replacement therapy. In: Yearbook of Intensive Care and Emergency Medicine. Vincent JL (Ed). Berlin, Springer Verlag, 2005, pp 349-359
23. Golper TA, Marx MA: Drug dosing adjustments during continuous renal replacement therapies. Kidney Int Suppl 1998; 66: S165-S168
24. Golper TA: Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Contrib Nephrol 2001; 349-353
25. Guenter SG, Iven H, Boos C, et al: Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy 2002; 22:175-183
26. Malone RS, Fish DN, Abraham E, et al: Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001; 45: 2949-2954
27. Hansen E, Bucher M, Jakob W, et al: Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Intensive Care Med 2001; 27:371-375
28. Traunmüller F, Thalhammer-Scherrer R, Locker GJ, et al: Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. J Antimicrob Chemother 2001; 47: 229-231
29. Choi G, Gomersall CD, Lipman J, et al: The effect of adsorption, filter material, and point of dilution on antibiotic elimination by haemofiltration: An in vitro study of levofloxacin. Int J Antimicrob Agents 2004; 24:468-472
30. Uchino S, Cole L, Morimatsu H, et al: Clearance of vancomycin during high-volume haemofiltration: Impact of pre-dilution. Intensive Care Med 2002; 28:1664-1667
31. Bohler J, Donauer J, Keller F: Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage. Kidney Int Suppl 1999; 72:S24-S28
32. Brunet S, Leblanc M, Geadah D, et al: Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34:486-492
33. Troyanov S, Cardinal J, Geadah D, et al: Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant 2003; 18:961-966
34. Pinder M, Bellomo R, Lipman J: Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30:134-144
35. Lipman J, Scribante J, Gous AG, et al: Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998; 42: 2235-2239
36. Wallis SC, Mullany DV, Lipman J, et al: Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 2001; 27:665-672
37. Fish DN, Teitelbaum I, Abraham E: Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005; 49: 2421-2428
38. Novelli A, Adembri C, Livi P, et al: Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44:539-549
39. Thalhammer F, Schenk P, Burgmann H, et al: Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998; 42:2417-2420
40. Krueger WA, Schroeder TH, Hutchison M, et al: Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998; 42: 2421-2424
41. Giles LJ, Jennings AC, Thomson AH, et al: Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000; 28:632-637
42. Krueger WA, Neeser G, Schuster H, et al: Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 2003; 49:280-286
43. Kielstein JT, Czock D, Schopke T, et al: Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34:51-56
44. Ververs TF, van Dijk A, Vinks SA, et al: Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000; 28:3412-3416
45. Joynt GM, Lipman J, Gomersall CD, et al: The pharmacokinetics of once daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47:421-429
46. Young RJ, Lipman J, Gin T, et al: Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997; 40:269-273
47. Isla A, Gascon AR, Maynar J, et al: In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy 2007; 53: 194-201
48. Hassan E, Ober JD: Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Antimicrob Agents Chemother 1987; 31:1855-1858
49. Davis R, Markham A, Balfour JA: Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51:1019-1074
50. Jones EM, McMullin CM, Hedges AJ, et al: The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: The effect of renal function and intra-abdominal disease. J Antimicrob Chemother 1997; 40:121-124
51. Bugge JF: Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001; 45:929-934
52. Tian Q, Gomersall CD, Ip M, et al: Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother 2008; 52: 1009-1013
53. Meyers BR, Srulevitch ES, Jacobson J, et al: Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob Agents Chemother 1983; 24: 812-814
54. Seddon M, Wise R, Gillett AP, et al: Pharmacokinetics of Ro 13-9904, a broadspectrum cephalosporin. Antimicrob Agents Chemother 1980; 18:240-242
55. Gonzalez MA, Moranchel AH, Duran S, et al: Multiple-dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther 1985; 37:633-637
56. Chow AT, Fowler C, Williams RR, et al: Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001; 45:2122-2125
57. de Pont AC: Extracorporeal treatment of intoxications. Curr Opin Crit Care 2007; 13:668-673
58. Tian Q, Gomersall CD, Leung PP, et al: The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters. Artif Organs 2008; 32:81-84
59. Gilbert DN, Moellering R, Eliopoulos G, et al: The Sanford Guide To Antimicrobial Therapy. Thirty-Seventh Edition. Sperryville, VA, Antimicrobial Therapy, 2007
60. Leone M, Albanese J, Sampol-Manos E, et al: Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother 2004; 48:638-640
61. Song JH, Jung SI, Ko KS, et al: High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP Study). Antimicrob Agents Chemother 2004; 48:2101-2107
62. Ambrose PG, Grasela DM, Grasela TH, et al: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45:2793-2797
63. Mueller BA, Pasko DA, Sowinski KM: Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27:808-814
64. Trotman RL, Williamson JC, Shoemaker DM, et al: Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41:1159-1166
65. Kitzes-Cohen R, Farin D, Piva G, et al: Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002; 19:105-110
66. Cunha B: Antibiotic Essentials. Sixth Edition. Royal Oak, MI, Physicians Press, 2007, pp 61-64
67. Ricci Z, Ronco C, D'Amico G, et al: Practice patterns in the management of acute renal failure in the critically ill patient: An international survey. Nephrol Dial Transplant 2006; 21:690-696
68. Selimoglu E: Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007; 13:119-126
69. Drusano GL, Ambrose PG, Bhavnani SM, et al: Back to the future: Using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45:753-760
70. Pannu N, Nadim MK: An overview of druginduced acute kidney injury. Crit Care Med 2008; 36:S216-S223
71. Rubinstein E, Camm J: Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49:593-596
72. Chow K, Hui A, Szeto C: Neurotoxicity induced by beta-lactam antibiotics: From bench to bedside. Eur J Clin Microbiol Infect Dis 2005; 24:649-653
73. Drusano GL: Infection site concentrations: Their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 2005; 25:150S-158S
74. Schentag JJ: Clinical pharmacology of the fluoroquinolones: Studies in human dynamic/kinetic models. Clin Infect Dis 2000; 31:S40-S44
75. Rybak MJ: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42:S35-S39
76. Andes D, van Ogtrop ML, Peng J, et al: In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46:3484-3489
77. Bouman CS, van Kan HJ, Koopmans RP, et al: Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006; 32:2013-2019
78. Capellier G, Cornette C, Boillot A, et al: Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit Care Med 1998; 26:88-91
79. Keller E, Bohler J, Busse-Grawitz A, et al: Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients. Clin Nephrol 1995; 43:S20-S23
80. Arzuaga A, Maynar J, Gascon AR, et al: Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005; 45:168-176
81. Mueller SC, Majcher-Peszynska J, Hickstein H, et al: Pharmacokinetics of piperacillintazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002; 46:1557-1560
82. Lindsay CA, Bawdon R, Quigley R: Clearance of ticarcillin-clavulanic acid by continuous venovenous hemofiltration in three critically ill children, two with and one without concomitant extracorporeal membrane oxygenation. Pharmacotherapy 1996; 16:458-462
83. Meyer B, Ahmed el Gendy S, Delle Karth G, et al: How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res 2003; 26:135-140
84. Davies SP, Lacey LF, Kox WJ, et al: Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis. Nephrol Dial Transplant 1991; 6:971-976
85. Weiss LG, Cars O, Danielson BG, et al: Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol 1988; 30:282-286
86. Traunmuller F, Schenk P, Mittermeyer C, et al: Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002; 49:129-134
87. Matzke GR, Frye RF, Joy MS, et al: Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000; 44:1639-1644
88. Mariat C, Venet C, Jehl F, et al: Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: Pharmacokinetic evaluation and dose recommendation. Crit Care 2006; 10:R26
89. Kroh UF, Lennartz H, Edwards DJ, et al: Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol 1996; 36: 1114-1119
90. Isla A, Gascon AR, Maynar J, et al: Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther 2005; 27: 599-608
91. Malone RS, Fish DN, Abraham E, et al: Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001; 45:3148-3155
92. Keller E, Fecht H, Bohler J, et al: Singledose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Nephrol Dial Transplant 1989; 4:640-645
93. Tegeder I, Bremer F, Oelkers R, et al: Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother 1997; 41:2640-2645
94. Hashimoto S, Honda M, Yamaguchi M, et al: Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ASAIO J 1997; 43:84-88
95. Vos MC, Vincent HH, Yzerman EP: Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Intensive Care Med 1992; 18:282-285
96. Mueller BA, Scarim SK, Macias WL: Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 1993; 21:172-179
97. Tegeder I, Neumann F, Bremer F, et al: Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999; 65:50-57
98. Isla A, Maynar J, Sanchez-Izquierdo JA, et al: Meropenem and continuous renal replacement therapy: In vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol 2005; 45:1294-1304
99. Langgartner J, Vasold A, Gluck T, et al: Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008; 34:1091-1096
100. Robatel C, Decosterd LA, Biollaz J, et al: Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol 2003; 43:1329-1340
101. Fuhrmann V, Schenk P, Jaeger W, et al: Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 2004; 54:780-784
102. Barrie JR, Mousdale S: Ciprofloxacin levels in a patient undergoing veno-venous haemodiafiltration. Intensive Care Med 1992; 18:437-438
103. Joy MS, Matzke GR, Frye RF, et al: Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 1998; 31:1019-1027
104. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004; 58: 259-268
105. Macias WL, Mueller BA, Scarim SK: Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance. Clin Pharmacol Ther 1991; 50:688-694
106. Boereboom FT, Ververs FF, Blankestijn PJ, et al: Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 1999; 25:1100-1104
107. Yagasaki K, Gando S, Matsuda N, et al: Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration. Intensive Care Med 2003; 29:2094-2095
108. Pea F, Brollo L, Lugano M, et al: Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Drug Monit 2001; 23:587-588
109. Wolter K, Claus M, Fritschka E: Pharmacokinetics and dosage recommendations of teicoplanin in patients treated by continuous veno-venous haemodialysis (CVVHD). Eur J Clin Pharmacol 1994; 46:179-180
110. Zarowitz BJ, Anandan JV, Dumler F, et al: Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol 1986; 26:686-689
111. Ernest D, Cutler DJ: Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med 1992; 20:586-589
112. Syka M, Markantonis SL, Mathas C, et al: A pilot study of netilmicin pharmacokinetics during continuous venovenous hemodiafiltration. J Clin Pharmacol 2005; 45:477-481
113. Robert R, Rochard E, Malin F, et al: Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med 1991; 19:588-589
114. Moon SY, Oh KH, Oh YK, et al: Removal of amikacin in patients undergoing continuous venovenous haemodiafiltration. Korean J Nephrol 2006; 25:595-601
115. Li J, Rayner CR, Nation RL, et al: Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49:4814-4815
116. Fiaccadori E, Maggiore U, Rotelli C, et al: Removal of linezolid by conventional intermittent hemodialysis, sustained lowefficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32:2437-2442
117. Pea F, Viale P, Lugano M, et al: Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: A report of 2 cases. Am J Kidney Dis 2004; 44:1097-1102
118. Meyer B, Kornek GV, Nikfardjam M, et al: Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 2005; 56:172-179
119. Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006; 24:548-554